Opiant Pharmaceuticals Revenue 2011-2026 | OPNT

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Opiant Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
47.8 M	29.6 M	40.5 M	14 M	18.4 M	9.9 M	1.55 M	-	-	173 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
173 M	1.55 M	41.8 M

Quarterly Revenue Opiant Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	174 K	3.89 M	4.47 M	-	16.3 M	11.3 M	6.39 M	-	9.11 M	6.31 M	4.28 M	-	20.6 M	6.77 M	5.44 M	-	4.37 M	3.15 M	1.7 M	13.5 M	22 K	3.77 M	22 K	6.86 M	1.12 M	6.98 M	1.12 M	560 K	120 K	560 K	120 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
20.6 M	22 K	5.15 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Amarin Corporation plc AMRN	214 M	$ 14.67	-0.07 %	$ 6.09 B	Irlanda
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Arena Pharmaceuticals ARNA	54 K	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	29.5 M	-	-	$ 546 M	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Cabaletta Bio CABA	0.006	$ 2.82	1.44 %	$ 283 M	USA
Avid Bioservices CDMO	140 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	242 K	$ 1.29	-3.01 %	$ 329 M	Britain
CEL-SCI Corporation CVM	255 K	$ 3.47	-1.7 %	$ 221 M	USA
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
Denali Therapeutics DNLI	331 M	$ 19.74	-12.17 %	$ 3.25 B	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	21 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	32.2 M	-	-	$ 3.74 B	USA
Enochian Biosciences ENOB	42.8 K	-	-	$ 40.5 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Equillium EQ	41.1 M	$ 2.06	-	$ 118 M	USA
Esperion Therapeutics ESPR	403 M	$ 2.85	3.26 %	$ 592 M	USA
Eton Pharmaceuticals ETON	80 M	$ 23.45	-1.64 %	$ 631 M	USA
China SXT Pharmaceuticals SXTC	4.78 M	$ 1.32	-5.2 %	$ 1.88 M	China
CRISPR Therapeutics AG CRSP	3.51 M	$ 47.55	0.98 %	$ 4.28 B	Schweiz
Arbutus Biopharma Corporation ABUS	14.1 M	$ 4.45	-1.77 %	$ 853 M	Canada